Pyxis and ZoBio go Dutch in US drug discovery collaboration

Collaboration agreement

Two Dutch companies, Pyxis Discovery and Leiden University spin-out ZoBio, have initiated a fragment-based drug discovery project in collaboration with the US oncology specialist NewLink Genetics of Ames, Iowa, for the discovery of new drugs targeting immunomodulatory pathways involved in cancer and infectious diseases.

In the project, ZoBio’s proprietary fragment screening technology, TINS, will be applied to screen a fragment library of Pyxis Discovery against multiple targets provided by NewLink Genetics, to identify novel lead molecules.